Medication before surgery for jaw tumor with BRAF mutation
Part of Cancer clinical trials.
This trial tests whether taking two targeted pills before surgery can shrink a rare jaw tumor (ameloblastoma) with a specific gene change, possibly allowing a less extensive operation. It compares this approach to surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have a confirmed jaw tumor (ameloblastoma) that is solid, cystic, or has come back after treatment.
- Your tumor has a specific gene change called BRAF V600E.
- Your doctor plans to remove part of your jaw or upper jaw as part of your treatment.
- You are generally healthy and able to care for yourself (ECOG 0-1).
- You have not had treatment with drugs like dabrafenib or trametinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests whether giving targeted therapy before and after surgery helps people with a specific type of lung cancer (non-small cell lung cancer with a BRAF or MET mutation). The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This trial tests a combination of two drugs (benmelstobart and anlotinib) given with standard chemotherapy before surgery in people with advanced mouth cancer. The goal is to see if this combination can shrink the tumor and improve the chance of successful treatment.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
Hear when a new Ameloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.